Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Completed Phase 4 Interventional

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

NCT06346288
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Breast Milk Sampling, Risankizumab
Procedure · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

NCT00348283
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2011 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease

NCT00234741
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326 mesylate
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2008 · Synced Oct 20, 2026, 10:05 PM EDT
Withdrawn Phase 3 Interventional

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

NCT02974322
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
136
States / cities
Litchfield Park, Arizona • Mesa, Arizona • Phoenix, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 20, 2026, 10:05 PM EDT
Recruiting No phase listed Observational

Mucosal and Microbiota Changes During Acute Campylobacteriosis

NCT03223077
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Recruiting Phase 4 Interventional

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

NCT07612267
View directory record Official record
Conditions
Lactation, Inflammatory Bowel Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Weeks and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Glenview, Illinois • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

NCT02895100
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PTG-100, Placebo
Drug
Lead sponsor
Protagonist Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Los Angeles, California • Colorado Springs, Colorado • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 20, 2026, 10:05 PM EDT
Active, not recruiting Not applicable Interventional Results available

A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis

NCT05739162
View directory record Official record
Conditions
Obesity, Ulcerative Colitis
Interventions
Apollo Endoscopic Suture System, Lifestyle Intervention
Device · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years to 69 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Placebo, MORF-057
Drug
Lead sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Industry
Eligibility
18 Years to 85 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

NCT02976129
View directory record Official record
Conditions
Crohn's Disease
Interventions
V565, Placebo
Drug
Lead sponsor
VHsquared Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Anaheim, California • Clearwater, Florida • Miami Springs, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

NCT01203631
View directory record Official record
Conditions
Inflammation, Crohn's Disease
Interventions
NNC 0142-0000-0002, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Anaheim, California • Lakewood, Colorado • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Effects of Relaxation Response Mind-body Intervention in Patients With IBS and IBD

NCT02136745
View directory record Official record
Conditions
Irritable Bowel Syndrome, Inflammatory Bowel Disease
Interventions
Relaxation Response Mind-Body Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

NCT02601300
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GED-0301
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Newport Beach, California • San Diego, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 20, 2026, 10:05 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

ImmuneSense™ IBD Study

NCT05769829
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Hialeah, Florida • Miami, Florida • Uniontown, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 20, 2026, 10:05 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Lutikizumab, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
48
States / cities
Chula Vista, California • Coronado, California • Huntington Beach, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 3 Interventional

Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067457
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
190
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 20, 2026, 10:05 PM EDT
Not listed Phase 4 Interventional

Folic Acid in Pediatric Inflammatory Bowel Disease

NCT03860012
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Folic Acid
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

NCT01177410
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 20, 2026, 10:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cell Transplantation in Crohn's Disease

NCT04224558
View directory record Official record
Conditions
Crohn Disease
Interventions
Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
Drug · Procedure · Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years to 28 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 20, 2026, 10:05 PM EDT
Completed No phase listed Observational

Entyvio (Vedolizumab) Long Term Safety Study

NCT02674308
View directory record Official record
Conditions
Ulcerative Colitis and Crohn's Disease
Interventions
Vedolizumab, Other Biologic Agents
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440385
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
81
States / cities
Scottsdale, Arizona • La Jolla, California • Lancaster, California + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

NCT00101946
View directory record Official record
Conditions
Crohn's Disease
Interventions
683699
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Garden Grove, California • Roseville, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

NCT00094458
View directory record Official record
Conditions
Crohn Disease
Interventions
infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps
Biological · Other · Drug
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
21 Years to 99 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 20, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PillCam® Platform With the PillCam Crohn's Disease Capsule

NCT01631435
View directory record Official record
Conditions
Crohn's Disease
Interventions
Pillcam colon capsule and PillCam™ Prep Procedure, Ileocolonoscopy
Other · Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 20, 2026, 10:05 PM EDT